Neuspera Medical Inc.

Neuspera Medical, Inc. is a medical technology company that specializes in advanced energy systems for ultra-miniaturized, minimally invasive implantable devices aimed at treating chronic illnesses. The company has developed a pioneering neurostimulation technology, with its flagship product being the first integrated sacral neuromodulation (iSNM) system designed specifically for urinary urge incontinence (UUI). This system received FDA approval in June 2025, enhancing treatment options for patients with overactive bladder. The core technology platform focuses on discreet, implantable devices that provide personal control and symptom relief through neuromodulation. Neuspera's iSNM system is designed for minimal invasiveness and optimized therapeutic effects through directional energy delivery. The company also holds FDA clearance for treating chronic pain of peripheral nerve origin, indicating its technology's broader application potential. Neuspera Medical aims to empower patients by offering adaptable treatment options that improve their quality of life.

• Employees 39
• Founded 2013
• Annual Revenue $11000000
• Total Funding $135603145